Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen

Abstract

Background: This observational study investigated whether the connected NovoPen® 6 could influence insulin regimen management and glycemic control in people with type 1 diabetes (T1D) using a basal-bolus insulin regimen and continuous glucose monitoring in a real-world setting. Methods: Participants from 12 Swedish diabetes clinics downloaded pen data at each visit (final cohort: n = 94). Outcomes included time in range (TIR; sensor glucose 3.9-10.0 mmol/L), time in hyperglycemia (>10 mmol/L), and hypoglycemia (L1: 3.0- <3.9 mmol/L; L2: <3.0 mmol/L). Missed bolus dose (MBD) injections were meals without bolus injection within -15 and +60 min from the start of a meal. Outcomes were compared between the baseline and follow-up periods (≥5 health care professional visits). Data were analyzed from the first 14 days following each visit. For the TIR and total insulin dose analyses (n = 94), a linear mixed model was used, and for the MBD analysis (n = 81), a mixed Poisson model was used. Results: TIR significantly increased (+1.9 [0.8; 3.0]95% CI h/day; P < 0.001) from baseline to follow-up period, with a corresponding reduction in time in hyperglycemia (-1.8 [-3.0; -0.6]95% CI h/day; P = 0.003) and L2 hypoglycemia (-0.3 [-0.6; -0.1]95% CI h/day; P = 0.005), and no change in time in L1 hypoglycemia. MBD injections decreased by 43% over the study (P = 0.002). Change in MBD injections corresponded to a decrease from 25% to 14% based on the assumption that participants had three main meals per day. Conclusions: Our study highlights the potential benefit on glycemic control and dosing behavior when reliable insulin dose data from a connected pen contribute to insulin management in people with T1D.

Keywords: Adherence; Connected insulin pen; Glycemic control; Hypoglycemia; Time in range.

Conflict of interest statement

P.A. has received research support or advisory board fees from Eli Lilly, Novo Nordisk, Roche, funding from Research and Development, Region Halland, and is an employee of Region Halland.

N.V.H., A.K., and J.B.M. are full-time employees of, and hold stock in, Novo Nordisk A/S.

J.H. has received advisory board fees from Abbott, Bayer, Sanofi, Novo Nordisk, Eli Lilly, MSD, and Boehringer Ingelheim and received consultancy fees from Sanofi, Novo Nordisk, and Boehringer Ingelheim.

Figures

FIG. 1.

Study design. Prebaseline was the period before study commencement where participants were already using CGM, but without concurrent use of the NovoPen® 6. CGM, continuous glucose monitoring; isCGM, intermittently scanned continuous glucose monitoring.

FIG. 2.

Upload of participant CGM data. Study period for each participant. A total of 94 participants are included in the TIR analysis. Blue lines indicate the period where data are available from the baseline date (blue square) to the last date with either CGM or insulin dosing data in the database. The filled blue circles indicate visits to the clinic, where data were downloaded and evaluated with the HCP. Orange lines indicate days with acceptable CGM data* within 1–14 days that are included in the primary analysis. The open blue circles are virtual uploads of CGM data that were not physical HCP visits. *CGM coverage of at least 70% per day. CGM, continuous glucose monitoring; HCP, health care professional; TIR, time in range.

FIG. 3.

Detection of missed bolus insulin doses by the GRID algorithm. Example of a day with two meals detected. The solid dark blue line represents the CGM signal and the light blue shaded areas each represent a detected meal. The gray, dashed line represents a glucose level of 7.2 mmol/L (130 mg/dL) and the gray shaded area represents a target glycemic range of 3.9–10.0 mmol/L (70–180 mg/dL). Meals are detected when the CGM signal is ≥7.2 mmol/L (≥130 mg/dL) and with rate-of-change being sufficiently high over the last two to three readings corresponding. The blue circles in the lower figure indicate bolus doses. A bolus dose within 15 min before to 60 min after a meal starts is considered “on-time,” whereas a dose outside of this time window is considered a MBD. Male patient, aged 30 at baseline. CGM, continuous glucose monitoring; GRID, Glucose Rate Increase Detector; MBD, missed bolus dose.

FIG. 4.

Mean difference in the time spent in glycemic ranges from baseline to after five HCP visits. *P < 0.05. Estimated mean difference in time spent in glycemic ranges with 95% CI. The difference is observed between baseline and ≥5 HCP visits. Baseline is the period after treatment initiation but before the first visit. Analysis is based on CGM data from a 14-day interval after each visit (≥70% coverage). Patients ≥18 years (n = 94) are included. CGM, continuous glucose monitoring; CI, confidence interval; HCP, health care professional; n, number; TIHyper, time in hyperglycemia; TIHypo L1, time in L1 hypoglycemia; TIHypo L2, time in L2 hypoglycemia; TIR, time in range.

FIG. 5.

Mean number of daily meals and dosing behaviors from baseline to after 5 HCP visits. Estimated mean number of daily meals with 95% CI. MBD are meals with missed bolus doses. “On-time” doses are meals where a bolus dose is taken. Undetected are meals that are not detected by the CGM signal, assuming an average of three meals per day. CGM, continuous glucose monitoring; CI, confidence interval; HCP, health care professional; MBD, missed bolus dose; NS, not significant.